SCHEDULE 13G: Oramed Pharmaceuticals Discloses 6.2% Passive Stake in Scilex Holding Company

Oramed Pharmaceuticals Inc. has reported a 6.2% beneficial ownership stake in Scilex Holding Company, comprising common stock and exercisable warrants.

Summary

• Oramed Pharmaceuticals Inc. (the "Reporting Person") has acquired beneficial ownership of 15,500,000 shares of Scilex Holding Company (the "Issuer").
• This ownership represents 6.2% of Scilex Holding Company's common stock.
• The stake is comprised of 9,000,000 shares of common stock and 6,500,000 shares issuable upon the exercise of warrants, which are exercisable within 60 days of the filing date.
• The percentage of class beneficially owned is calculated based on 243,312,885 shares of Common Stock outstanding as of January 6, 2025, as represented by the Issuer, plus the 6,500,000 shares issuable from warrants held by the Reporting Person.
• Oramed Pharmaceuticals Inc. holds sole voting power and sole dispositive power over all 15,500,000 beneficially owned shares.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would indicate a positive or negative sentiment regarding the issuer's performance or outlook.

Positives

• Scilex Holding Company has attracted a significant beneficial ownership stake from Oramed Pharmaceuticals Inc., indicating a notable investment interest in the company.

Negatives

• No specific negative operational or financial information regarding Scilex Holding Company was disclosed in this beneficial ownership report.

Risks

• The filing does not detail specific risks related to Scilex Holding Company's operations or financial health, as it is a beneficial ownership disclosure focused on the Reporting Person's stake.

Future Outlook

This Schedule 13G filing, a beneficial ownership report, does not contain any forward-looking statements or guidance regarding Scilex Holding Company's future outlook.

Management Comments

• Oramed Pharmaceuticals Inc. certified that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, nor in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.

Industry Context

This filing indicates a significant investment by Oramed Pharmaceuticals Inc., a Delaware-based pharmaceutical company, into Scilex Holding Company, also operating in the pharmaceutical sector. Such cross-company investments can signal strategic alignment or confidence within the industry, though this specific filing indicates a passive stake and not an active attempt to influence control.

Comparison to Industry Standards

• This beneficial ownership filing does not provide financial or operational results that can be directly compared to industry standards or specific comparable companies/projects.

Stakeholder Impact

• Shareholders of Scilex Holding Company: Awareness of a significant passive investor, Oramed Pharmaceuticals Inc., holding 6.2% of the common stock.
• Oramed Pharmaceuticals Inc. Shareholders: Disclosure of a significant investment in Scilex Holding Company.

Next Steps

• The document is a regulatory filing disclosing beneficial ownership and does not outline specific future actions, events, or milestones for either the issuer or the reporting person.

Key Dates

Keywords

Scilex Holding Company, Oramed Pharmaceuticals, Schedule 13G, Beneficial Ownership, Common Stock, Warrants, SEC Filing, Pharmaceutical, Biotechnology, Investment